Prochlorperazine Maleate Tablet, Film Coated
NDC Package 69452-310-32
Package Information
Prochlorperazine Maleate tablets is a medication used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). This formulation utilizes a tablet, film coated delivery system. Marketed by Bionpharma Inc., this product is identified by NDC 69452-310 and is authorized under FDA application ANDA217478.
Identification & Billing
- RxCUI: 198365 - prochlorperazine maleate 10 MG Oral Tablet
- RxCUI: 198365 - prochlorperazine 10 MG Oral Tablet
- RxCUI: 198365 - prochlorperazine (as prochlorperazine maleate) 10 MG Oral Tablet
- RxCUI: 312635 - prochlorperazine maleate 5 MG Oral Tablet
- RxCUI: 312635 - prochlorperazine 5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69452 - Bionpharma Inc.
- 69452-310 - Prochlorperazine Maleate
- 69452-310-32 - 1000 TABLET, FILM COATED in 1 BOTTLE
- 69452-310 - Prochlorperazine Maleate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (69452-310). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69452-310-32 identifies a specific commercial package of 1000 tablet, film coated in 1 bottle of Prochlorperazine Maleate, a human prescription drug labeled by Bionpharma Inc.. This tablet, film coated is formulated for oral use and contains prochlorperazine maleate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bionpharma Inc. on September 13, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.
How is this Bionpharma Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69452031032. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.